Additionally, DYRK1B depletion or inhibition in ovarian, lung, and pancreatic cancer cells rendered cells sensitive to chemotherapeutics that induce reactive oxygen species (ROS), such as cisplatin [70, 81–83]. This evidence concerns the gene DYRK1B and pancreatic neoplasm.